Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andrew Beelen"'
Autor:
Michael Danso, Joyce O’Shaughnessy, Lisa S. Wang, Kailash Mosalpuria, Sara Hurvitz, Shom Goel, Sarah Ahn, Subing Cao, John S. Yi, Taofik Oyekunle, Amanda Jacobson, Andrew Beelen, Jeremy Force
Publikováno v:
Cancer Research. 83:P3-06
Background: In early-stage triple-negative breast cancer (TNBC), there is accumulating evidence of a correlation between tumor-infiltrating lymphocytes in tumor tissue and favorable clinical outcomes, with a high CD8+/regulatory T-cell (Treg) ratio a
Autor:
Chao, Li, Benjamin, Rich, Julie M, Bullock, Olivier, Barrière, Jean-Francois, Marier, Andrew, Beelen
Publikováno v:
British Journal of Clinical Pharmacology. 89:1067-1079
Trilaciclib is a first-in-class, intravenous cyclin-dependent kinase 4/6 inhibitor that provides multilineage protection from chemotherapy-induced myelosuppression. This analysis aimed to characterize the population pharmacokinetics (PK) of trilacicl
Autor:
Shom Goel, Antoinette R Tan, Hope S Rugo, Philippe Aftimos, Zoran Andrić, Andrew Beelen, Jingshan Zhang, John S Yi, Rajesh Malik, Joyce O'Shaughnessy
Publikováno v:
Future oncology (London, England). 18(33)
Triple-negative breast cancer (TNBC) is an aggressive malignancy for which cytotoxic chemotherapy remains the backbone of treatment. Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor that induces transient cell cycle arrest of hemat
Publikováno v:
Clinical drug investigation. 42(8)
Trilaciclib is a cyclin-dependent kinase 4/6 inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small-cell lung cancer. Trilaciclib is a substrate and time-dependent inhibitor of cy